Oncology

  • 10 December 2019
    News

    Merck to acquire ArQule in $2.7bn deal

    Merck (MSD) has signed a definitive agreement to acquire biopharmaceutical company ArQule for a total cash consideration of $2.7bn, or $20 per share.

Close
Close
Close

Go Top